M. Miyazaki

发表

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin

T. Satoh, I. Okamoto, K. Okamoto, 2011, International Journal of Clinical Oncology.

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

R. Kaiser, K. Azuma, I. Okamoto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kaoru Tanaka, K. Azuma, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

I. Okamoto, K. Nakagawa, K. Yonesaka, 2010, Lung cancer.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer

M. Satouchi, H. Nakayama, I. Okamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors

I. Okamoto, K. Nakagawa, T. Seriu, 2011, Cancer science.

Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.

Toshio Shimizu, M. Fukuoka, K. Tamura, 2007, Anticancer research.

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.

M. Seike, M. Okada, S. Morita, 2021, The Lancet. Respiratory medicine.

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

K. Azuma, K. Yoshimori, Satoshi Watanabe, 2020, EBioMedicine.

Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer

T. Mukohara, K. Takeda, S. Negoro, 2001, Cancer Chemotherapy and Pharmacology.

Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer

T. Kudo, I. Okamoto, K. Nakagawa, 2013 .

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

I. Okamoto, K. Kunimasa, K. Nakagawa, 2010, International Journal of Clinical Oncology.

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors

Toshio Shimizu, M. Fukuoka, K. Tamura, 2009, Cancer Chemotherapy and Pharmacology.

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

J. Sakamoto, N. Masuda, T. Satoh, 2013, Breast Cancer.

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors

A. Ohtsu, Ken Kobayashi, I. Okamoto, 2009, Japanese journal of clinical oncology.

Phase I Clinical and Pharmacokinetic Study of RAD 001 ( Everolimus ) Administered Daily to Japanese Patients with Advanced Solid Tumors

A. Ohtsu, Ken Kobayashi, I. Okamoto, 2009 .

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

A. Gemma, M. Okada, S. Morita, 2019, The Lancet. Oncology.

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

M. Fukuoka, Hirokazu Watanabe, T. Taguchi, 2009, Clinical Cancer Research.

Regional differences in the prevalence of sensitization to environmental allergens: Analysis on IgE antibody testing conducted at major clinical testing laboratories throughout Japan from 2002 to 2011.

M. Taniguchi, Y. Fukutomi, K. Sekiya, 2019, Allergology international : official journal of the Japanese Society of Allergology.

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

M. Fukuoka, A. Kawada, T. Satoh, 2009, Investigational New Drugs.

Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors.

T. Satoh, I. Okamoto, Y. Sakata, 2010, Japanese journal of clinical oncology.

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

Toshio Shimizu, I. Okamoto, K. Nakagawa, 2010, Investigational New Drugs.

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

M. Kitaichi, I. Okamoto, K. Nakagawa, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study

N. Saijo, M. Fukuoka, T. Satoh, 2007 .

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)

M. Fukuoka, M. Satouchi, S. Kudoh, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

N. Ikeda, M. Fukuoka, H. Saka, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan

M. Fukuoka, T. Satoh, Y. Hasegawa, 2007 .

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

K. Nishio, T. Satoh, T. Tsunoda, 2012, Cancer science.

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

R. Kaiser, K. Nishio, T. Satoh, 2010, Molecular Cancer Therapeutics.

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer

R. Kaiser, K. Yoh, K. Goto, 2015, Cancer Chemotherapy and Pharmacology.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer

J. Tanizaki, K. Okamoto, K. Nakagawa, 2015, Cancer science.